Ana Sayfa
Piyasalar
Grafikler ve Fikirler
Algo
Haberler
Store
Aracı Kurumlar
İndir
Ekonomik Takvim
Alım-Satım Sinyalleri
Web Terminali
Heatmap
Arama yapmak için
/
tuşuna basın: @kullanıcı, $sembol, ...
Ara
Giriş yap
Hesap oluştur
Türkçe
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
TRVI
#2046
Trevi Therapeutics, Inc. Common Stock
14.0
4
USD
+5.33%
Sektör:
Sağlık Hizmetleri
Baz:
USD
Kar Para Birimi:
USD
Günlük Aralık
Yıllık Aralık
Günlük Değişim
+5.33%
Aylık Değişim
+25.25%
6 aylık değişim
+36.31%
Yıllık Değişim
+131.68%
Önceki Kapanış
13.3
3
Open
14.0
4
Bid
Ask
Low
14.0
4
High
14.0
4
Hacim
100
Piyasalar
ABD Borsası
Sağlık Hizmetleri
TRVI
Open full chart
Financials
Overview
Rapor
Statistics
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
19.91 M
30.81 M
60.05 M
68.96 M
96.68 M
128.4 M
—
Valuation ratios
Enterprise value
17.15 M
1.75 M
118.45 M
57.25 M
364.23 M
1.59 B
3.87 B
Price to earnings ratio
—
—
-4.51
-4.48
-8.77
-39.13
-90.86
Price to sales ratio
—
—
—
—
—
—
—
Price to cash flow ratio
—
—
-4.65
-4.06
-10.98
-40.08
-96.03
Price to book ratio
—
—
1.22
1.56
4.22
9.21
14.62
Enterprise value to EBITDA ratio
—
—
-3.93
-1.69
-7.09
-32.3
-76.98
Profitability ratios
Return on assets %
-0.7
-0.88
-0.24
-0.33
-0.43
-0.22
-0.26
Return on equity %
-1.2
-1.99
-0.27
-0.35
-0.48
-0.23
-0.27
Return on invested capital %
-17.06 K
-3 448.17
-1 709.43
-2 827.93
-10.51 K
-10.24 K
-12.68 K
Gross margin %
—
—
—
—
—
—
—
Operating margin %
—
—
—
—
—
—
—
EBITDA margin %
—
—
—
—
—
—
—
Net margin %
—
—
—
—
—
—
—
Liquidity ratios
Quick ratio
—
—
—
—
—
—
—
Current ratio
8.33
2.98
9.15
15.03
10.41
19.66
79.4
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
—
—
0
0
0
0
0
Solvency ratios
Debt to assets ratio
0.3
0.38
0.07
—
—
—
—
Debt to equity ratio
0.51
0.85
0.09
—
—
—
—
Long term debt to total assets ratio
0.3
0.38
0.07
—
—
—
—
Long term debt to total equity ratio
0.51
0.85
0.09
—
—
—
—
Per share metrics
Operating cash flow per share
—
—
-0.44
-0.32
-0.38
-0.31
-0.32
EBIT per share
—
—
-0.46
-0.34
-0.51
-0.37
-0.37
EBITDA per share
—
—
-0.47
-0.34
-0.5
-0.37
-0.37
Total debt per share
—
—
0.14
—
—
—
—
Cash per share
—
—
1.87
0.84
1.06
1.4
5.18
Net current asset value per share
—
—
1.9
0.88
1.07
1.42
5.28
Tangible book value per share
—
—
1.66
0.83
0.98
1.36
5.04
Working capital per share
—
—
1.69
0.83
0.97
1.35
5.01
Book value per share
—
—
1.66
0.83
0.98
1.36
5.04
Haberler
Needham, Trevi Therapeutics için hedef fiyatı yükseltti
Cantor Fitzgerald, Trevi Therapeutics hissesi için Ağırlıklı Al tavsiyesini yineledi
Trevi Therapeutics, Inc. (TRVI) Q4 2025 Earnings Call Transcript
Trevi Therapeutics 4Ç 2025 kazancı beklentileri aştı
Zacks.com featured highlights include Trevi, Metalla Royalty & Streaming and Vermilion
Trevi Therapeutics hissesine Oppenheimer’dan Faz 3 planları sonrası destek
Trevi Therapeutics stock gets Oppenheimer nod on Phase 3 plans
Up Over 50%: 3 Stocks on the Verge of a Massive Breakout in March
Trevi, IPF’de kronik öksürük tedavisi için iki Faz 3 denemesi planlıyor
Trevi plans two phase 3 trials for chronic cough treatment in IPF
Does Trevi Therapeutics (TRVI) Have the Potential to Rally 102.07% as Wall Street Analysts Expect?
Trevi’nin nalbuphine ER ilacı IPF öksürüğünde önemli azalma gösterdi